Capstone Therapeutics (CAPS) Stock Price, News & Analysis

Company Overview

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Key Stats

• Today's Range: $1.85 to $1.91
• 50-Day Range: $1.66 to $2.90
• 52-Week Range: $1.58 to $16.18
• Volume: 7,978 shs
• Average Volume: 34,165 shs
• Market Capitalization: $300.80 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CAPS Stock Analysis - Frequently Asked Questions

How have CAPS shares performed this year?

Capstone Therapeutics' stock was trading at $2.40 at the beginning of the year. Since then, CAPS shares have decreased by 21.7% and is now trading at $1.88.
View the best growth stocks for 2025 here.

When did Capstone Therapeutics IPO?

Capstone Therapeutics (CAPS) raised $5 million in an IPO on Thursday, March 6th 2025. The company issued 1,250,000 shares at $4.00 per share.

How do I buy shares of Capstone Therapeutics?

Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CAPS
• CIK: 887151
• Web: N/A
• Phone: (708) 371-0660
• Fax: 602-286-5300
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 1.14
• Quick Ratio: 0.47

Sales & Book Value

• Annual Sales: $44.88 million
• Price / Sales: 0.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($19.40) per share
• Price / Book: -0.10

Miscellaneous

• Outstanding Shares: 160,000
• Free Float: 90,000
• Market Cap: $300.80 thousand
• Optionable: N/A
• Beta: -0.83